WO2014036312A3 - Immunosignaturing: a path to early diagnosis and health monitoring - Google Patents

Immunosignaturing: a path to early diagnosis and health monitoring Download PDF

Info

Publication number
WO2014036312A3
WO2014036312A3 PCT/US2013/057373 US2013057373W WO2014036312A3 WO 2014036312 A3 WO2014036312 A3 WO 2014036312A3 US 2013057373 W US2013057373 W US 2013057373W WO 2014036312 A3 WO2014036312 A3 WO 2014036312A3
Authority
WO
WIPO (PCT)
Prior art keywords
health
health monitoring
molecules
immunosignaturing
path
Prior art date
Application number
PCT/US2013/057373
Other languages
French (fr)
Other versions
WO2014036312A2 (en
WO2014036312A8 (en
Inventor
Stephen Albert Johnston
Phillip Stafford
Neal Woodbury
Original Assignee
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University filed Critical Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University
Priority to GB1504970.3A priority Critical patent/GB2525743A/en
Priority to CN201380056857.9A priority patent/CN104781668B/en
Priority to AU2013308682A priority patent/AU2013308682A1/en
Priority to CA2882801A priority patent/CA2882801C/en
Priority to EP13833992.4A priority patent/EP2890984B1/en
Priority to JP2015530060A priority patent/JP6463678B2/en
Publication of WO2014036312A2 publication Critical patent/WO2014036312A2/en
Publication of WO2014036312A8 publication Critical patent/WO2014036312A8/en
Publication of WO2014036312A3 publication Critical patent/WO2014036312A3/en
Priority to AU2019204047A priority patent/AU2019204047C1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00659—Two-dimensional arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00729—Peptide nucleic acids [PNA]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Health Is a complex state that represents the continuously changing outcome of nearly all human activities and interactions. This disclosure provides efficient methods and arrays for health monitoring, diagnosis, treatment, and preventive care. The present disclosure also provides methods to monitor a broad range of identifying molecules from a subject, such as circulating antibodies, and the evaluate a pattern of binding of those molecules to a peptide array. The characterization of the binding patterns of such molecules to a peptide array utilizing the present method provides a robust measure of a state of health of a subject.
PCT/US2013/057373 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring WO2014036312A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB1504970.3A GB2525743A (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring
CN201380056857.9A CN104781668B (en) 2012-08-29 2013-08-29 Immune characteristic is analyzed：Lead to the approach of early diagnosis and health monitoring
AU2013308682A AU2013308682A1 (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring
CA2882801A CA2882801C (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring
EP13833992.4A EP2890984B1 (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring
JP2015530060A JP6463678B2 (en) 2012-08-29 2013-08-29 Immune signature: methods for early diagnosis and health monitoring
AU2019204047A AU2019204047C1 (en) 2012-08-29 2019-06-11 Immunosignaturing: a path to early diagnosis and health monitoring

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261694598P 2012-08-29 2012-08-29
US61/694,598 2012-08-29

Publications (3)

Publication Number Publication Date
WO2014036312A2 WO2014036312A2 (en) 2014-03-06
WO2014036312A8 WO2014036312A8 (en) 2015-04-09
WO2014036312A3 true WO2014036312A3 (en) 2015-05-14

Family

ID=50184639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/057373 WO2014036312A2 (en) 2012-08-29 2013-08-29 Immunosignaturing: a path to early diagnosis and health monitoring

Country Status (8)

Country Link
US (2) US20140087963A1 (en)
EP (1) EP2890984B1 (en)
JP (2) JP6463678B2 (en)
CN (2) CN104781668B (en)
AU (2) AU2013308682A1 (en)
CA (1) CA2882801C (en)
GB (1) GB2525743A (en)
WO (1) WO2014036312A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CA2758481C (en) 2009-04-30 2018-03-20 Patientslikeme, Inc. Systems and methods for encouragement of data submission in online communities
US10046293B2 (en) * 2012-10-17 2018-08-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona In situ chemical patterning
JP6503966B2 (en) * 2015-08-05 2019-04-24 株式会社島津製作所 Multivariate analysis result display device
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
US20180284114A1 (en) * 2015-10-02 2018-10-04 Arizona Board Of Regents On Behalf Of Arizona State University Methods for processing biopolymeric arrays
EP3373950B1 (en) 2015-11-11 2024-05-01 Serimmune Inc. Methods and compositions for assessing antibody specificities
WO2017223116A2 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
CA3028975A1 (en) * 2016-06-20 2017-12-28 Healthtell Inc. Methods for diagnosis and treatment of autoimmune diseases
WO2018089556A1 (en) 2016-11-09 2018-05-17 Healthtell Inc. Coatings with tunable amine density
WO2018089858A1 (en) 2016-11-11 2018-05-17 Healthtell Inc. Methods for identifying candidate biomarkers
WO2018144571A2 (en) 2017-01-31 2018-08-09 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic to distinguish bacterial infections
JP2020522479A (en) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ Methods for making personalized cancer vaccines
US20200209241A1 (en) * 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020033271A1 (en) 2018-08-06 2020-02-13 Arizona Board Of Regents On Behalf Of Arizon State University Computational analysis to comprehensively predict and design molecular recognition between peptides and proteins
US11894139B1 (en) 2018-12-03 2024-02-06 Patientslikeme Llc Disease spectrum classification
WO2020223368A1 (en) * 2019-04-29 2020-11-05 Nautilus Biotechnology, Inc. Methods and systems for integrated on-chip single-molecule detection
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
WO2023056466A1 (en) * 2021-10-01 2023-04-06 Arizona Board Of Regents On Behalf Of Arizona State University Machine learning approaches to enhance disease diagnostics
US11680293B1 (en) 2022-04-21 2023-06-20 Paragon Genomics, Inc. Methods and compositions for amplifying DNA and generating DNA sequencing results from target-enriched DNA molecules

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020678A1 (en) * 2002-10-30 2007-01-25 Dana Ault-Riche Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
US20120190574A1 (en) * 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759774A (en) * 1988-05-18 1998-06-02 Cobe Laboratories, Inc. Method of detecting circulating antibody types using dried or lyophilized cells
US5449754A (en) * 1991-08-07 1995-09-12 H & N Instruments, Inc. Generation of combinatorial libraries
US6346423B1 (en) * 1999-07-16 2002-02-12 Agilent Technologies, Inc. Methods and compositions for producing biopolymeric arrays
WO2001056691A2 (en) * 2000-02-03 2001-08-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Method and device for the synthesis and the analysis of support-bound arrays of oligomers, especially of primer pairs for pcr, as well as oligomer-carrying supports
CN1438324A (en) * 2003-03-10 2003-08-27 东南大学 Microarray chip of oligonucleotide and its preparing method
US20050255491A1 (en) * 2003-11-13 2005-11-17 Lee Frank D Small molecule and peptide arrays and uses thereof
WO2006124644A2 (en) * 2005-05-12 2006-11-23 Board Of Regents, The University Of Texas System Protein and antibody profiling using small molecule microarrays
DE102005060920A1 (en) * 2005-12-18 2007-06-21 Charité - Universitätsmedizin Berlin Peptides for interaction with alpha-helical coiled-coil structures and / or coiled-coil sequences, means derived therefrom and their use
US20100210478A1 (en) * 2006-06-29 2010-08-19 Xiaolian Gao Make and use of surface molecules of varied densities
JP2008063285A (en) * 2006-09-08 2008-03-21 Univ Nagoya Method for designing and preparing high-affinity peptide, and the resultant high-affinity peptide
US20080188618A1 (en) * 2007-01-23 2008-08-07 Greving Matthew P Porous Acrylate Copolymer Films and Uses Therefor
US20090176664A1 (en) * 2007-06-01 2009-07-09 Keting Chu High density peptide arrays containing kinase or phosphatase substrates
EP2145898A1 (en) * 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
WO2010043668A1 (en) * 2008-10-17 2010-04-22 Zentech S.A. Dried blood spots for blood analysis
WO2011150168A1 (en) * 2010-05-28 2011-12-01 Gen9, Inc. Methods and devices for in situ nucleic acid synthesis
JP5872569B2 (en) * 2010-10-27 2016-03-01 キャピタルバイオ コーポレーションＣａｐｉｔａｌＢｉｏ Ｃｏｒｐｏｒａｔｉｏｎ Molecules labeled with luminophores coupled to particles for microarray-based assays

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020678A1 (en) * 2002-10-30 2007-01-25 Dana Ault-Riche Methods for producing polypeptide-tagged collections and capture systems containing the tagged polypeptides
US20120190574A1 (en) * 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
WO2011109440A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics

Also Published As

Publication number Publication date
GB201504970D0 (en) 2015-05-06
CA2882801C (en) 2022-01-18
AU2019204047A1 (en) 2019-06-27
AU2019204047B2 (en) 2021-08-05
AU2019204047C1 (en) 2021-11-18
AU2013308682A1 (en) 2015-03-12
GB2525743A (en) 2015-11-04
EP2890984A2 (en) 2015-07-08
EP2890984A4 (en) 2016-05-25
CN104781668A (en) 2015-07-15
CA2882801A1 (en) 2014-03-06
US20200256861A1 (en) 2020-08-13
WO2014036312A2 (en) 2014-03-06
US20140087963A1 (en) 2014-03-27
JP2019012072A (en) 2019-01-24
WO2014036312A8 (en) 2015-04-09
JP2015535336A (en) 2015-12-10
JP6873950B2 (en) 2021-05-19
EP2890984B1 (en) 2018-10-03
CN104781668B (en) 2018-07-24
JP6463678B2 (en) 2019-02-06
CN108957005A (en) 2018-12-07

Similar Documents

Publication Publication Date Title
WO2014036312A3 (en) Immunosignaturing: a path to early diagnosis and health monitoring
WO2016094904A8 (en) Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
WO2014127065A3 (en) Facial expression measurement for assessment, monitoring, and treatment evaluation of affective and neurological disorders
WO2007098070A3 (en) Non-invasive methods for evaluating retinal affecting neurodegenerative diseases
GB2535034A (en) Methods and systems for microbiome characterization, monitoring and treatment
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
BR112013022493A2 (en) equipment and method for examining, diagnosing or assisting in the diagnosis and treatment of functional vision problems
EP3697925A4 (en) Identification and use of biological parameters for diagnosis and treatment monitoring
WO2013117656A3 (en) Apparatus and method for calibrating invasive electric desynchronizing neurostimulation
WO2010042831A3 (en) Diagnosis, prognosis and treatment of glioblastoma multiforme
IN2014CN05002A (en)
WO2011141765A8 (en) Diagnostic classifications of pulse signal waveform data
WO2011113428A3 (en) Method for determining the activity of the parasympathetic nervous system and/or the sympathetic nervous system of the autonomic nervous system of a living being
WO2011156734A3 (en) Method of characterizing vascular diseases
WO2017027391A3 (en) Genetic abnormalities in plasma cell dyscrasias
WO2011127917A3 (en) Device and method for treating diseases of the brain and/or of the spinal cord by means of neurofeedback
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
DE102017010318B8 (en) Esophageal electrode probe and device for cardiac treatment and / or diagnosis
WO2013011294A3 (en) Diagnosis of alzheimer's disease
WO2017025617A8 (en) Method for the quantification of faecalibacterium prausnitzii phylogroup i and/or phylogroup ii members and the use thereof as biomarkers
WO2015038634A3 (en) Multiplex diagnostic assay for lyme disease and other tick-borne diseases
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2014052685A3 (en) Devices and methods for single cell analysis
AU2015268674A1 (en) Spectral sensing of ablation
WO2011019757A3 (en) Methods of monitoring endoplasmic reticulum (er) stress response

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13833992

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2882801

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015530060

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013308682

Country of ref document: AU

Date of ref document: 20130829

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1504970

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20130829

WWE Wipo information: entry into national phase

Ref document number: 1504970.3

Country of ref document: GB